Risk Assessment for HBV-Related Liver Cancer

Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07160946

Enrollment

6000

Registered

2025-09-08

Start date

2025-05-10

Completion date

2032-12-30

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-related Liver Cirrhosis

Brief summary

Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.

Interventions

OTHERAI folow-up system

In AI follow-up group, patients will be followed up by an AI system.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 75 Years

Healthy volunteers

Inclusion criteria

must meet (a) and any one of (b) to (g). * (a).Positive for Hepatitis B surface antigen; (b).Ultrasound/CT/MR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis/ liver cancer; (e). Long term alcohol consumption history (\>5 years), equivalent to alcohol consumption of ≥ 40g/d for males and ≥ 20g/d for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.

Exclusion criteria

* (a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time\<1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.

Design outcomes

Primary

Measure	Time frame	Description
Number and specific time of participants progressing to liver cancer	5 years	Number and specific time of participants progressing to liver cancer

Secondary

Measure	Time frame	Description
Survival time	5 years	Participants' survival time after being diagnosed with liver cancer.

Other

Measure	Time frame	Description
Incidence of adverse events for the participants	5 years	Incidence of ascite, hepatorenal system, hepatic encephalopathy, gastrointestinal bleeding, etc. for all the participants.

Countries

China

Contacts

Primary ContactBingliang Prof. Lin

linbingl@mail.sysu.edu.cn+86-20-85252081

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026